Drug intelligence / Profile preview

GSK2236805

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules

Overview

GSK2236805 is a potent inhibitor of the hepatitis C virus (HCV), specifically targeting HCV genotypes 1a and 1b. It is not explicitly mentioned as a NS5A inhibitor in the provided sources for this specific compound, but it is noted as an HCV inhibitor.

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on GSK2236805.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2236805.

Explore the full profile